5-azacytidine
Recurrent Uterine Carcinosarcoma
Ohio State University Comprehensive Cancer CenterPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Uterine Carcinosarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rucaparib Ohio State University Comprehensive Cancer Center | Phase 1 | CC |
Mirvetuximab Soravtansine Ohio State University Comprehensive Cancer Center | Phase 1 | CC |
Same molecule, other indications
5-azacytidine is also rated in:
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →